Business
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma was awarded oral and poster presentations at World Antiviral Congress 2022. Oral Presentation Details:Title: Showcase 6: Mechanism based designed 3CL inhibitors. From HRV to Covid19Date: 30th of November, 2022Time: 3:45pm PTRoom: Commodore A & BLoews Coronado Bay Resort, San Diego Poster Presentation Details:Title: NLC-V (Tollovir™) as an Adjunctive Therapy in Hospitalized Patients Diagnosed with COVID-19: A Phase 2 Randomized, Double-Blind, Placebo-controlled TrialDate: 30th of November 2022Exhibition HallLoews Coronado Bay Resort To learn more about the 3CL protease in SARS-CoV-2 replication, please visit www.3clpro.com. To purchase Tollovid please visit Amazon or www.MyTollovid.com. About Todos Medical Ltd.Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel analyses, and Provista's proprietary commercial-stage Videssa® breast cancer blood test. More information on Provista is available at www.provistadx.com. Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces the...